骨質疏鬆症治療市場：依藥物類型、給藥途徑、通路及地區分類

2025 年全球骨質疏鬆症治療市場規模估計為 155.7 億美元，預計到 2032 年將達到 210.6 億美元，2025 年至 2032 年的複合年成長率為 4.4%。

數字。 2025 年骨質疏鬆症治療市場佔有率（按地區分類）

骨質疏鬆症是一種以骨量低和骨組織結構劣化為特徵的疾病，導致骨骼變弱並增加骨折風險。該疾病已成為全球醫學界關注的一大議題，尤其對老年族群而言。壽命延長、久坐的生活方式和營養攝取不足等因素是導致已開發國家和開發中國家骨質疏鬆症盛行率上升的主要原因。根據《Frontiers》雜誌發表的資料，全球有超過2億人患有骨質疏鬆症。由於目前尚無治療方法，終身藥物治療在治療和預防骨折方面發揮重要作用。為了滿足這項尚未滿足的需求，全球骨質疏鬆症治療市場在過去幾十年來穩步成長。

市場動態

預計骨質疏鬆症高風險的老年人數量將增加，從而推動全球對骨質疏鬆症治療的需求。根據聯合國估計，到 2050 年，65 歲以上的人口預計將增加一倍以上。人們對骨質疏鬆症篩檢和管理的認知不斷提高、新產品的推出以及對高風險患者的診斷不斷增加，將進一步推動市場成長。然而，重磅藥物的專利到期和對學名藥的偏好繼續抑制市場的成長。同時，改善新興國家的醫療保健服務也帶來了龐大的機會。

研究的主要特點

• 本報告對全球骨質疏鬆症治療市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），以 2024 年為基準年。
• 它強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 全球骨質疏鬆症治療市場的主要企業簡介是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行的。
• 主要企業包括 Teva Pharmaceutical Industries Ltd.、DAIICHI SANKYO COMPANY, LIMITED、Amgen Inc.、Dr. Reddy's Laboratories Ltd.、Viatris Inc.、Ligand Pharmaceuticals Incorporated、Eli Lilly and Company、Asahi Kasei Corporation、F. HM. Hr. 、Pfizer Inc.、Enzene Biosciences、Apotex Inc. 等。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
• 全球骨質疏鬆症治療市場迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過全球骨質疏鬆症治療市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管情景
• 製造商收益
• 收購和合作場景
• 產品發布/核准
• 資金籌措和投資
• PEST分析
• 波特的分析

4. 全球骨質疏鬆症治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020-2032 年全球骨質疏鬆症治療市場（按藥物類型分類）（十億美元）

• 介紹
• 雙磷酸鹽
• 抑鈣素，荷爾蒙療法
• 選擇性雌激素受體調節(SERM)
• 副甲狀腺素相關蛋白 (PTHrP) 類似物
• 其他

6. 2020 年至 2032 年全球骨質疏鬆症治療市場（依給藥途徑分類）（十億美元）

• 介紹
• 口服
• 注射
• 其他

7. 2020-2032 年全球骨質疏鬆症治療市場按分銷管道分類（十億美元）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年全球骨質疏鬆症治療市場（按地區分類）（十億美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Osteoporosis Treatment Market is estimated to be valued at USD 15.57 Bn in 2025 and is expected to reach USD 21.06 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032.

Figure. Osteoporosis Treatment Market Share (%), By Region 2025

Osteoporosis is a condition characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. The disease has become a major global healthcare concern, especially among the elderly population. Factors such as increasing life expectancy, sedentary lifestyles, and improper nutrition have contributed significantly to rising prevalence of osteoporosis across both developed and developing nations. According to data published by Frontiers, over 200 million people worldwide suffer from osteoporosis. With no curative treatment currently available, lifelong management through pharmacotherapy plays a crucial role in treatment and prevention of fractures. Global osteoporosis treatment market has witnessed steady growth over the past couple of decades to meet this unmet need.

Market Dynamics:

Growing geriatric population who are at high risk of osteoporosis is expected to boost demand for osteoporosis treatment drugs globally. According to the United Nations, the population aged 65 years and above is expected to more than double by 2050. Rising awareness about osteoporosis screening and management, new product launches, and increasing at-risk patient diagnosis are further propelling the market growth. However, patent expiries of blockbuster drugs and preference for generic drugs continue to restrain the market growth. Meanwhile, significant opportunities lie in emerging economies due to growing accessibility of healthcare.

Key Features of the Study:

• This report provides an in-depth analysis of the global osteoporosis treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global osteoporosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global osteoporosis treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market.

Detailed Segmentation-

• By Drug Type:
  • Bisphosphonates
  • Calcitonin, Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Others
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Osteoporosis Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Osteoporosis Treatment Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Bisphosphonates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcitonin, Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Selective Estrogen Receptor Modulators (SERMs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Osteoporosis Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Osteoporosis Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Osteoporosis Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • DAIICHI SANKYO COMPANY, LIMITED
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ligand Pharmaceuticals Incorporated
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"